The offering provides a cash lifeline for FDA submission but imposes massive dilution. Monitor for Nasdaq listing compliance and warrant exercise activity. Further dilution risk remains if warrants are exercised, adding overhang.
Price Chart
Executive Summary
Bluejay Diagnostics announced a private placement raising $8.5 million upfront (up to $23.6 million with warrant exercise), priced at $2.325 per share. The offering is highly dilutive given the company's $2 million market cap, but the proceeds extend cash runway into Q1 2027, supporting FDA submission efforts.
Key Financial Metrics
Key Facts
- Private placement of 3,655,917 shares plus series G and H warrants at $2.325 per unit
- Gross proceeds of $8.5 million upfront, up to $15.1 million additional from warrant exercise
- Net proceeds expected to extend cash runway into Q1 2027; if warrants fully exercised, beyond FDA approval and first year of commercialization
- Offering priced at-the-market under Nasdaq rules; dilution is substantial relative to current market cap of $2M
- H.C. Wainwright & Co. acted as exclusive placement agent
- Proceeds to fund FDA approval activities (clinical studies), R&D, and working capital
Financial Impact
Immediate $8.5M gross proceeds; potential total $23.6M if all warrants exercised. Dilution of roughly 80%+ based on pre-offering share count implied by market cap.
Risk Factors
- Extreme dilution to existing shareholders
- FDA approval uncertainty could lead to further capital needs
- Warrant overhang if exercised could pressure stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305486 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5601 (−32.70%) |
Oct 6, 2026 20d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5601 (−30.91%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5601 (−47.16%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5601 (−47.16%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5601 (−50.87%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5601 (−54.09%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5601 (−61.37%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5601 (+61.10%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5601 (+87.44%) |
Jun 9, 2026 19w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5601 (−87.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers